visibility
Back to School Support
Back to School Support Work with your child’s health care provider to meet your child’s unique eczema needs  As children return to the classroom, hand washing and mask protocols will be part of the new normal. ESC recognizes...
visibility
Atopic Dermatitis Patient Journey Shines Light on Shared Patient Experience
Atopic Dermatitis Patient Journey Shines Light on Shared Patient Experience ESC is delighted to share its report The Atopic Dermatitis Patient Journey, which takes a comprehensive look at the eczema patient experience in...
visibility
ESC advocates for patients during drug pricing discussions 
ESC advocates for patients during drug pricing discussions ESC recently learned that proposed changes to the way drug prices are set in Canada (also know as Patented Medicines Regulations) may negatively impact Canadians living with...
visibility
Canadian researchers find new approach to treating eczema
Canadian researchers find new approach to treating eczema ESC Research Grant Recipient discovers key enzyme that contributes to atopic dermatitis Researchers at University of British Colombia’s faculty of medicine have discovered a...
visibility
“A Day with Eczema” receives CDA Award
“A Day with Eczema” receives Canadian Dermatology Association (CDA) Award Campaign sheds light on burden of condition and its impact on daily life ESC is delighted to share that their awareness campaign “A Day with Eczema”...
visibility
ESC announces 2019 Research Grant Program recipients
ESC announces 2019 Research Grant Program recipients ESC is pleased to announce the recipients of our 2019 Research Grant Program. We received applications from researchers from with leading universities across Canada. This...
visibility
Summer Sunscreen Tips
Summer Sunscreen Tips Suitable sunscreens can be challenging to find to people with sensitive skin and eczema. Avoiding the peak sun of the mid-day, wearing a hat, and dressing in protective clothing are all great ideas for practicing...
visibility
Dupilumab Now Available for Adolescents Aged 12 and Older
Dupilumab (Dupixent™) Now Available for Adolescents Aged 12 and Older ESC is pleased to share that last fall, Health Canada approved dupilumab (brand name Dupixent™) for the treatment of moderate-to-severe atopic dermatitis (AD) in...
visibility
New patient-friendly online resource compares systemic therapies for treatment of atopic dermatitis
New patient-friendly online resource compares systemic therapies for treatment of atopic dermatitis Data aims to help patients and health care providers understand treatment options for atopic dermatitis (eczema) patients New...

ESC is hosting a new webinar series this fall, focusing on tackling eczema flares and support for the caregiver. Learn more or register now!

La SCE organise une nouvelle série de webinaires cet automne (en anglais), afin de s’attaquer aux poussées d’eczéma et d’apporter un soutien aux aidants. Apprenez-en plus ou inscrivez-vous dès maintenant!